---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-024346"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2024-03-04T23:59:59+00:00"
generated_at: "2026-06-05T04:36:50.963525+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# EyePoint names Ramiro Ribeiro as Chief Medical Officer, replaces Dario Paggiarino

## Summary
- Ramiro Ribeiro appointed CMO effective March 1, 2024; succeeds Dario Paggiarino who leaves March 31.
- Ribeiro joins from Apellis, where he led global Phase 3 GA program and FDA approval of SYFOVRE.
- Company on track to report Phase 2 PAVIA topline data for EYP-1901 in NPDR in Q2 2024.
- Initiation of Phase 3 LUGANO trial for EYP-1901 in wet AMD expected in second half 2024.
- Board granted 125,000 stock options as inducement award to Ribeiro under Nasdaq Rule 5635(c)(4).

## SEC filing metadata
- accession: 0000950170-24-024346
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2024-03-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017024024346/0000950170-24-024346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017024024346/eypt-20240304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-024346
- JSON: https://secwatch.observer/filing/0000950170-24-024346.json
- Plain text: https://secwatch.observer/filing/0000950170-24-024346.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.